Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02097225 ↗

Phase 1 Terminated 22 enrolled National Cancer Institute (NCI)

Non-randomizedSequentialOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of onalespib when given together with dabrafenib and trametinib in treating patients with BRAF-mutant melanoma or solid tumors that have spread to another place in the body (metastatic) or cannot be removed by surgery. Onalespib, dabrafenib, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2014-05-29
Primary completion: 2019-03-31
Completion: 2022-10-26

Publications

Mooradian MJ, Cleary JM, Giobbie-Hurder A, Darville LNF, Parikh A, Buchbinder EI, Cohen JV, Lawrence DP, Shapiro GI, Keer H, Chen HX, Ivy SP, Smalley KSM, Koomen JM, Sullivan RJ. Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors. Cancer. 2023 Jun 15;129(12):1904-1918. doi: 10.1002/cncr.34730. Epub 2023 Apr 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dabrafenib	Small molecule	75 mg	Oral
Subject	Dabrafenib	Small molecule	150 mg	Oral
Subject	Onalespib	Small molecule	180 mg/m2	Intravenous
Subject	Onalespib	Small molecule	220 mg/m2	Intravenous
Subject	Onalespib	Small molecule	260 mg/m2	Intravenous
Subject	Trametinib	Small molecule	1 mg	Oral
Subject	Trametinib	Small molecule	2 mg	Oral

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Summary

Timeline

Publications

Drugs

Indications